Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
HeraMED Limited specializes in digital health solutions, particularly focusing on remote monitoring for pregnant women through its proprietary HeraBEAT device. The company operates primarily in Australia and is positioned to capitalize on the growing demand for telehealth services, especially in maternal care.
HeraMED generates revenue through the sale of its HeraBEAT device, which allows for continuous fetal monitoring. The company also offers subscription services for data analytics and remote monitoring, providing a recurring revenue stream. Its competitive advantage lies in its innovative technology and the ability to provide real-time health data to both patients and healthcare providers.
Regulatory approvals for new devices or software enhancements
Partnerships with healthcare providers or insurance companies
Market adoption rates of telehealth services
Changes in maternal health policies or funding
Technological disruption from competitors offering advanced telehealth solutions
Regulatory changes impacting telehealth reimbursement policies
Emergence of new entrants in the digital maternal health space
Established medical device companies expanding into telehealth
Negative cash flow impacting liquidity
High operating losses leading to potential funding challenges
moderate - Demand for healthcare services is generally stable, but economic downturns can impact consumer spending on non-essential health services.
Interest rates affect HeraMED's ability to finance operations and R&D. Higher rates could increase borrowing costs, impacting cash flow and investment in growth.
minimal - The company has a manageable debt-to-equity ratio of 0.45, indicating limited reliance on credit markets.
growth - Investors are likely attracted to the company's potential for rapid revenue growth in the telehealth sector.
high - The stock has exhibited significant price volatility, evidenced by a 254.5% return over the past year.
